CSBio CSBio

X
[{"orgOrder":0,"company":"Hibiskus BioPharma","sponsor":"Lodo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lodo Therapeutics Acquires Hibiskus Biopharma AND Licenses Rights to Novel Proteasome Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals for TIR-199

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            With this acquisition, Lodo expands its preclinical pipeline with selective proteasome inhibitors with potential application in solid tumor cancers and other indications. Logo gains exclusive license to intellectual property from university of california.

            Lead Product(s): TIR-199

            Therapeutic Area: Oncology Product Name: LODO-141

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Lodo Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition September 03, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY